Blue Jet Healthcare logo

Blue Jet Healthcare

BLUEJET NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹10,685 Cr
Volatility
Moderate
P/E Ratio
41.96
EBITDA
₹215 Cr
Return on Equity
39.96%
Debt to Equity
0.03
Book Value
₹114.11
EPS
₹9.47
52W High
₹722.7
52W Low
₹325

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.6%

Weaknesses

1
  • Stock is trading at 7.25 times its book value

Growth Rate

Revenue Growth
-6.62% lower than 3Y
Net Income Growth
-6.34% lower than 3Y
Cash Flow Change
5.34%
ROE
-44.11%
ROCE
-38.82%
EBITDA Margin (Avg.)
4.83%

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 41d ago
AI opinion · based on fundamentals
Risk high

Blue Jet Healthcare is an almost debt-free specialty pharma intermediates company with a market cap of ~₹12,000 Cr trading at a PE of 47.9x. Revenue declined 8% on a TTM basis and net profit fell 17% YoY (FY26 PAT ₹248 Cr vs ₹305 Cr in FY25), though the company maintains a 3-year ROE of 24% and is investing ₹2,300 Cr in a greenfield facility for future growth.

Bull Case 8
  • Almost debt-free balance sheet provides financial flexibility and low interest burden (interest cost just ₹6.2 Cr in FY26 on ₹332 Cr EBITDA)
  • Strong 3-year ROE track record of 24% and 5-year ROE of 26%, indicating efficient capital deployment
  • Contrast Media intermediates revenue grew 23% YoY in FY26 to ₹495 Cr, demonstrating diversification strength
  • Q4 FY25 EBITDA margins climbed to 41%, up 1,190 bps YoY, showing operating leverage potential
  • Compounded sales CAGR of 14% over 5 years reflects solid medium-term topline growth trajectory
  • ₹2,300 Cr greenfield facility in Andhra Pradesh positions the company for CDMO and capacity expansion
  • Gross margins improved to 54.9% in Q4 FY25, up 160 bps YoY, indicating better product mix
  • Compounded profit CAGR of 16% over 3 years despite recent cyclical downturn
Bear Case 8
  • TTM revenue declined 8% and FY26 revenue fell to ₹947 Cr from ₹1,030 Cr in FY25, indicating demand softness
  • Net profit dropped 17% on TTM basis — FY26 PAT of ₹248 Cr vs ₹305 Cr in FY25
  • Stock trades at 7.99x book value and 47.9x PE, demanding premium valuation despite earnings decline
  • Working capital days increased sharply from 158 days to 224 days, signaling cash conversion deterioration
  • Stock price declined 21% over the past 1 year, reflecting market skepticism on near-term growth
  • Q1 FY27 revenue fell 17.7% YoY with profit down 14.2%, suggesting the downturn is continuing
  • Planned ₹1,000 Cr QIP fundraise may dilute existing shareholders during a period of weak earnings
  • Dividend yield of just 0.19% offers negligible income support at current valuation levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 41d ago
Headwinds 2
  • FY26 net profit drops 18.8% Jul 6

    Full-year net profit fell 18.8% to ₹2,478.16 million for FY26, with revenue declining 7.9% to ₹9,423.67 million.

  • Q1FY27 profit down 14.2% YoY Aug 3

    Q1FY27 net profit came in at ₹782.64 million, down 14.2% YoY, with revenue falling to ₹2,931.13 million.

Positives 2
  • EcoVadis Silver Medal won Jul 20

    Blue Jet awarded EcoVadis Silver Medal for sustainability with a score of 77, placing it in the top 15% globally.

  • ₹1.2 interim dividend approved Aug 3

    Board approved an interim dividend of ₹1.2 per share alongside Q1FY27 results announcement.

Neutral 3
  • QIP opened at ₹531.70 floor Jul 6

    Qualified Institutions Placement opened on July 6, 2026, with a floor price of ₹531.70 per share following Board and shareholder approvals.

  • Promoter confirms no encumbrance Jul 27

    Akshay Bansarilal Arora and PACs confirmed zero encumbrance on their 79.81% stake per SEBI Regulation 31(4) annual disclosure for FY26.

  • Q1FY27 earnings call scheduled Jul 28

    Analyst and investor conference call scheduled for August 3, 2026, at 5:30 PM IST to discuss Q1FY27 unaudited standalone results.

TL;DR: Blue Jet Healthcare is facing a clear earnings deterioration trend with both FY26 and Q1FY27 showing double-digit profit declines alongside falling revenues. The QIP at ₹531.70 suggests capital-raising needs, while the EcoVadis recognition and clean promoter holding structure are modest positives. The revenue contraction trend across multiple quarters is the key risk to monitor. Until top-line growth resumes, the earnings trajectory remains under pressure.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
180
181
167
184
163
208
318
340
355
165
192
235
293
Expenses
121
119
112
131
119
139
194
200
234
111
146
163
195
Operating Profit
59
63
55
53
44
69
124
140
121
55
47
71
98
OPM %
33%
35%
33%
29%
27%
33%
39%
41%
34%
33%
24%
30%
33%
Other Income
5
8
-3
9
9
12
13
12
8
24
13
23
15
Interest
0
0
0
0
0
0
0
0
1
5
0
1
1
Depreciation
6
6
8
8
3
5
5
5
6
6
6
6
7
PBT
58
64
44
54
49
77
132
147
123
69
54
87
106
Tax %
24%
26%
27%
27%
24%
24%
25%
25%
26%
24%
25%
26%
26%
Net Profit
44
48
32
40
38
58
99
110
91
52
40
64
78
EPS in Rs
2.54
2.76
1.85
2.29
2.18
3.36
5.71
6.35
5.26
3.01
2.32
3.71
4.51
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
538
499
683
721
712
1,030
947
886
Expenses
325
292
434
502
481
652
653
614
Operating Profit
214
207
249
219
231
378
294
271
OPM %
40%
41%
36%
30%
32%
37%
31%
31%
Other Income
6
9
19
24
18
46
69
76
Interest
7
5
3
1
0
0
6
6
Depreciation
18
20
22
25
28
18
24
25
PBT
194
190
243
217
220
406
333
316
Tax %
25%
26%
25%
26%
26%
25%
25%
—
Net Profit
145
142
182
160
164
305
248
235
EPS in Rs
24,118
1,429
10.47
9.23
9.44
17.59
14.29
13.55
Div. Payout %
0%
0%
0%
0%
11%
7%
8%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.6
10
35
35
35
35
35
Reserves
198
330
487
647
811
1,098
1,325
Borrowings
74
52
19
5
3
21
44
Other Liabilities
92
142
173
176
211
263
238
Total Liabilities
364
534
713
862
1,059
1,418
1,641
Fixed Assets
107
139
156
151
172
300
316
CWIP
2
3
3
30
147
89
301
Investments
26
37
94
189
250
187
252
Other Assets
229
355
460
491
489
841
771
Total Assets
364
534
713
862
1,059
1,418
1,641
Figures in ₹ Crores

Cash Flow

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
122
137
146
142
241
46
334
Investing
-45
-61
-76
-147
-264
-35
-276
Financing
-72
-21
-56
-4
-2
-19
-31
Net Cash Flow
5
55
14
-10
-24
-8
28
Free Cash Flow
106
85
125
83
68
-34
115
CFO/OP
80
66
70
92
109
36
151
Figures in ₹ Crores

Ratios

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
80
105
121
121
91
124
131
Inventory Days
120
253
133
137
151
209
157
Days Payable
90
128
72
58
35
70
48
Cash Conversion Cycle
110
231
183
199
206
262
240
Working Capital Days
55
89
103
120
92
157
136
ROCE %
—
58%
53%
35%
30%
40%
26%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Blue Jet Healthcare insights

62 extracted metrics + investor summaries across FY20–FY27.

Log in — free

Shareholding Pattern

FIIs0.62%Promot.73.14%Others7.02%DIIs9.12%Public10.09%As ofJun 2026

Documents

Frequently Asked Questions about Blue Jet Healthcare

What does Blue Jet Healthcare Ltd do?
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
Where is Blue Jet Healthcare Ltd (BLUEJET) listed?
Blue Jet Healthcare Ltd trades as BLUEJET on the NSE and under code 544009 on the BSE.
Which sector does Blue Jet Healthcare Ltd belong to?
Blue Jet Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has a market capitalisation of ₹10,685 Cr, which places it in the Mid Cap band.
What is the PE ratio of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd trades at a PE ratio of 41.96, on earnings per share of ₹9.47, against a book value of ₹114.11 per share.
What is the 52-week high and low of Blue Jet Healthcare Ltd?
Over the last 52 weeks Blue Jet Healthcare Ltd has traded between ₹325 and ₹722.7.
Does Blue Jet Healthcare Ltd pay dividends?
Blue Jet Healthcare Ltd has a dividend yield of 0.21%.
What is the Return on Equity (ROE) of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd reported a return on equity of 39.96%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]

Website bluejethealthcare.com
CEO Mr. Akshay Bansarilal Arora
Employees 196
Listed 2023-11-01
Face Value ₹ 2
Issued Size 17,34,65,425

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BLUEJET.md for Blue Jet Healthcare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List